Literature DB >> 8128841

Long-term treatment with tacrine (THA) in Alzheimer's disease--evaluation of neuropsychological data.

K Amberla1, A Nordberg, M Viitanen, B Winblad.   

Abstract

Long-term effects of tacrine (THA) on cognitive functions of very mild AD patients were studied. The stability of possible positive changes following prolonged treatment and the effect of increased dose was also studied. Three patients were treated with tacrine (80 mg/day) and the effect on cognitive functions was measured with a neuropsychological test battery. Two of the patients (Pats 1 and 4) showed clear positive changes in all parameters measured. The third patient (Pat 5) did not show as clear positive responses. The effect of the initial treatment dose diminished over time. After raising the dose two of the patients showed improvement in cognitive tests reaching their initial level of performance or even better in most of the tests. This positive effect was not as clear in patient 5. After 13 months of tacrine all patients still showed positive changes in some of the tests. Compared to a hypothetical progression curve for untreated AD patients the patients treated with tacrine seemed to have slower progression. In conclusion, it seems that long-term positive effects on cognitive functions of AD patients can be reached with tacrine and it seems to be possible to slow down the progression of the disease. However, to reach long-term positive effects increasing doses seem to be needed. AD patients seem to differ in their response to tacrine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8128841     DOI: 10.1111/j.1600-0404.1993.tb04257.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


  7 in total

Review 1.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

2.  Protective effect of Ginkgo biloba leaf extract on learning and memory deficit induced by aluminum in model rats.

Authors:  Qi-hai Gong; Qin Wu; Xie-nan Huang; An-sheng Sun; Jing Nie; Jing-shan Shi
Journal:  Chin J Integr Med       Date:  2006-03       Impact factor: 1.978

Review 3.  Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.

Authors:  A J Wagstaff; D McTavish
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

4.  Neuroprotective effect of hesperidin on aluminium chloride induced Alzheimer's disease in Wistar rats.

Authors:  Arokiasamy Justin Thenmozhi; Tharsius Raja William Raja; Udaiyappan Janakiraman; Thamilarasan Manivasagam
Journal:  Neurochem Res       Date:  2015-01-29       Impact factor: 3.996

5.  Exploring the Key Genes and Identification of Potential Diagnosis Biomarkers in Alzheimer's Disease Using Bioinformatics Analysis.

Authors:  Wuhan Yu; Weihua Yu; Yan Yang; Yang Lü
Journal:  Front Aging Neurosci       Date:  2021-06-14       Impact factor: 5.750

6.  EGCG Nanoparticles Attenuate Aluminum Chloride Induced Neurobehavioral Deficits, Beta Amyloid and Tau Pathology in a Rat Model of Alzheimer's Disease.

Authors:  Neha Atulkumar Singh; Vaishali Bhardwaj; Chandrika Ravi; Nithya Ramesh; Abul Kalam Azad Mandal; Zaved Ahmed Khan
Journal:  Front Aging Neurosci       Date:  2018-08-13       Impact factor: 5.750

7.  The protective effect of Indian Catechu methanolic extract against aluminum chloride-induced neurotoxicity, A rodent model of Alzheimer's disease.

Authors:  Ekramy Elmorsy; Eman Elsharkawy; Fahad A Alhumaydhi; Mohamed Salama
Journal:  Heliyon       Date:  2021-02-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.